ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,249.91
0.22%
Dow Jones
38,711.29
0.36%
Gold vs US Dollar
2,329.455
0.03%
Brent Oil
77.705
0.77%
Bitcoin
71,254.45
0.89%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Jazz Pharmaceuticals PLC (JAZZ)

  7. Jazz Pharmaceuticals PLC (JAZZ) News

Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:JAZZ
DateTimeSourceHeadlineSymbolCompany
03/06/202421:28Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:JAZZJazz Pharmaceuticals PLC
01/06/202413:05PR Newswire (US)Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
31/05/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:JAZZJazz Pharmaceuticals PLC
30/05/202412:30PR Newswire (US)Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
29/05/202421:15PR Newswire (US)Jazz Pharmaceuticals to Participate in Upcoming June Investor ConferencesNASDAQ:JAZZJazz Pharmaceuticals PLC
29/05/202421:15PR Newswire (US)Jazz Pharmaceuticals to Participate in Upcoming June Investor ConferencesNASDAQ:JAZZJazz Pharmaceuticals PLC
29/05/202412:45PR Newswire (US)Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract CancerNASDAQ:JAZZJazz Pharmaceuticals PLC
22/05/202413:00PR Newswire (US)Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee VolunteerismNASDAQ:JAZZJazz Pharmaceuticals PLC
07/05/202422:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
01/05/202421:10PR Newswire (US)Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care ConferenceNASDAQ:JAZZJazz Pharmaceuticals PLC
01/05/202421:10PR Newswire (US)Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care ConferenceNASDAQ:JAZZJazz Pharmaceuticals PLC
01/05/202421:05PR Newswire (US)Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial GuidanceNASDAQ:JAZZJazz Pharmaceuticals PLC
24/04/202421:05PR Newswire (US)Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
17/04/202421:15PR Newswire (US)Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
10/04/202412:45PR Newswire (US)Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual MeetingNASDAQ:JAZZJazz Pharmaceuticals PLC
02/04/202412:30PR Newswire (US)Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract CancerNASDAQ:JAZZJazz Pharmaceuticals PLC
12/03/202420:15PR Newswire (US)Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
12/03/202420:15PR Newswire (US)Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
08/03/202423:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
08/03/202402:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
08/03/202402:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
08/03/202402:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
08/03/202402:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
07/03/202423:09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
06/03/202400:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
06/03/202400:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
06/03/202400:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
06/03/202400:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
06/03/202400:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
06/03/202400:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:JAZZJazz Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:JAZZ

Your Recent History

BIT
P207X8
NLBNPIT207X8 20240619 4800
COIN
BTLEUR
BIT
S31855
Societe Generale Effekten
BITMOT
889566
Ifc Tf 6,75% Ag24 Brl
LSE
47AM
Municplty 40
BIT
P1ZQU2
NLBNPIT1ZQU2 20241220 700
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved